Download PDF
Hamostaseologie 2006; 26(02): 106-113
DOI: 10.1055/s-0037-1616889
Original article
Schattauer GmbH

Antithrombotische Therapie bei Nicht-ST-Hebungsinfarkt

Antithrombotic therapy for non-ST segment elevation myocardial infarction
H. Hölschermann
1   Innere Medizin I – Kardiologie / Angiologie, Hochtaunus-Kliniken, Krankenhaus Bad Homburg
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Der Myokardinfarkt ohne ST-Streckenhebung zählt zu den akut lebensbedrohlichen Manifestationen der koronaren Herzerkrankung. Eine kombinierte plättchenhemmende und antithrombotische Therapie (bestehend aus Azetylsalizylsäure, Clopidogrel, Heparin, und Glykoprotein-IIb/IIIa- Inhibititoren) zusammen mit einem früh-invasiven Vorgehen (d. h. Koronarangiographie und Stentimplantation innerhalb von 24-48 Stunden) verbessern das Ergebnis von Patienten mit akutem Nicht-ST-Hebungsinfarkt in der Primärversorgung. Durch eine duale Plättchenhemmung mit Clopidogrel und Azetylsalizylsäure wird das Risiko eines ischämischen Rezidivereignisses auch im Langzeitverlauf gesenkt. Eine antithrombotische Strategie wird in Zukunft idealerweise fatale Ereignisse vor einer Revaskularisation reduzieren und die Ergebnisse der perkutanen Koronarintervention verbessern können ohne gleichzeitig das Blutungsrisiko zu erhöhen.

Summary

Non-ST segment elevation myocardial infarction (NSTEMI) is an acute life-threatening event which has a high rate of recurrence. Combined antithrombotic therapy (including acetylsalicylic acid, clopidogrel, heparins and glycoprotein IIb/IIIa receptor antagonists) substantially reduced major coronary events during the acute phase of coronary heart disease with a good tolerance because of the short duration of such aggressive strategy. The combined antithrombotic strategy also allows to increase the benefit of an early invasive strategy including coronary angiogram with stent percutaneous coronary angioplasty which recent trials have shown that to be preferable to a conservative approach in these high risk patients. Antithrombotic and antiplatelet therapy in association with coronary revascularization play an important role in the prevention of an adverse outcome. Recently, clopidogrel has been shown reduce recurrent ischaemic events, both early and during the first year after non-ST-segment elevation myocardial infarction. An ideal antithrombotic and antiplatelet strategy will reduce events before revascularization, enhance the revascularization procedure without excessive bleeding.

Schlüsselwörter

Akutes Koronarsyndrom - antithrombotische Therapie

Keywords

Acute coronary syndrome - antithrombotic therapy
 

  • References

  • 1 A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996; 335: 775-82.
    CrossrefPubMedGoogle Scholar
  • 2 Andreotti F, Testa L, Biondi-Zoccai G. et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J. 2005
    PubMedGoogle Scholar
  • 3 Bittl JA, Chaitman BR, Feit F. et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9.
    CrossrefPubMedGoogle Scholar
  • 4 Blazing MA, de Lemos JA, White HD. et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004; 292: 55-64.
    CrossrefPubMedGoogle Scholar
  • 5 Boersma E, Harrington RA, Moliterno DJ. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359 9302 189-98.
    CrossrefPubMedGoogle Scholar
  • 6 Boeynaems JM, van Giezen H, Savi P. et al. P2Y receptor antagonists in thrombosis. Curr Opin Investig Drugs 2005; 6: 275-82.
    PubMedGoogle Scholar
  • 7 Cannon CP, Weintraub WS, Demopoulos LA. et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
    CrossrefPubMedGoogle Scholar
  • 8 Cohen M, Demers C, Gurfinkel EP. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
    CrossrefPubMedGoogle Scholar
  • 9 00. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
    CrossrefPubMedGoogle Scholar
  • 10 Coller BS, Peerschke EI, Scudder LE. et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
    CrossrefPubMedGoogle Scholar
  • 11 Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.. I. S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62.
    CrossrefPubMedGoogle Scholar
  • 12 De Winter RJ, Windhausen F, Cornel JH. et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353: 1095-104.
    CrossrefPubMedGoogle Scholar
  • 13 Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet 1999; 353 9151 429-38.
    CrossrefPubMedGoogle Scholar
  • 14 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
    CrossrefPubMedGoogle Scholar
  • 15 Ferguson JJ, Califf RM, Antman EM. et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
    PubMedGoogle Scholar
  • 16 Fox KA, Poole-Wilson PA, Henderson RA. et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360 9335 743-51.
    CrossrefPubMedGoogle Scholar
  • 17 Gurbel PA, Bliden KP, Hayes KM. et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-6.
    CrossrefPubMedGoogle Scholar
  • 18 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
    PubMedGoogle Scholar
  • 19 Hochholzer W, Trenk D, Frundi D. et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111: 2560-4.
    CrossrefPubMedGoogle Scholar
  • 20 Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Lancet 1994; 343 8893 311-22.
    PubMedGoogle Scholar
  • 21 Klein W, Buchwald A, Hillis SE. et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61-8.
    CrossrefPubMedGoogle Scholar
  • 22 Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
    CrossrefPubMedGoogle Scholar
  • 23 Lepantalo A, Virtanen KS, Heikkila J. et al. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. Eur Heart J 2004; 25: 476-83.
    CrossrefPubMedGoogle Scholar
  • 24 Lincoff AM, Bittl JA, Harrington RA. et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
    CrossrefPubMedGoogle Scholar
  • 25 Madan M, Tcheng JE. Update on Abciximab Readministration During Percutaneous Coronary Interventions. Curr Interv Cardiol Rep 2000; 2: 244-9.
    PubMedGoogle Scholar
  • 26 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 9281 527-33.
    CrossrefPubMedGoogle Scholar
  • 27 Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-25.
    CrossrefPubMedGoogle Scholar
  • 28 Oler A, Whooley MA, Oler J. et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-5.
    CrossrefPubMedGoogle Scholar
  • 29 Patti G, Colonna G, Pasceri V. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099-106.
    CrossrefPubMedGoogle Scholar
  • 30 Petersen JL, Mahaffey KW, Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004; 292: 89-96.
    PubMedGoogle Scholar
  • 31 Sanderson S, Emery J, Baglin T. et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142: 370-80.
    CrossrefPubMedGoogle Scholar
  • 32 Schror K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vasc Med 1998; 3: 247-51.
    CrossrefPubMedGoogle Scholar
  • 33 Shah PB, Ahmed WH, Ganz P. et al. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J Am Coll Cardiol 1997; 30: 1264-9.
    CrossrefPubMedGoogle Scholar
  • 34 Silber S, Albertsson P, Aviles FF. et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
    CrossrefPubMedGoogle Scholar
  • 35 Simoons ML, Bobbink IW, Boland J. et al. A dosefinding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004; 43: 2183-90.
    CrossrefPubMedGoogle Scholar
  • 36 Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31: 195-204.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18: 1587-93.
    CrossrefPubMedGoogle Scholar
  • 38 Wiviott SD, Antman EM, Winters KJ. et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)- TIMI 26 trial. Circulation 2005; 111: 3366-73.
    CrossrefPubMedGoogle Scholar
  • 39 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 494-502.
    PubMedGoogle Scholar